Literature DB >> 8086429

Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase.

C M Ensor1, H H Tai.   

Abstract

NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes the first step in the catabolic pathway of the prostaglandins. This enzyme oxidizes the 15-hydroxyl group of prostaglandins to produce 15-keto metabolites which are usually biologically inactive. In this study the cDNA for human placental 15-PGDH was expressed in Escherichia coli and the recombinant enzyme was purified to homogeneity and characterized. The N-terminus of the recombinant protein was sequenced and found to be identical with the known amino-acid sequence of 15-PGDH. Determinations of Km and Vmax values for a number of the prostaglandins and NAD+ indicate that the recombinant enzyme does not appear to be kinetically different from the human placental enzyme. Site-directed mutagenesis was used to examine the importance of two residues which are highly conserved in the short-chain dehydrogenases which are known to be related to 15-PGDH. Tyrosine-151 was changed to phenylalanine and serine while lysine-155 was changed to glutamine and leucine. Western blot analysis indicated that the mutant and wild-type proteins were expressed at the similar levels. However, all of the mutant proteins were found to be inactive. These results indicate that both tyrosine-151 and lysine-155 are required for 15-PGDH activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086429     DOI: 10.1016/0167-4838(94)90172-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.

Authors:  Guosheng Huang; Rosana Eisenberg; Min Yan; Stefano Monti; Earl Lawrence; Pingfu Fu; Jaclyn Walbroehl; Ester Löwenberg; Todd Golub; Jaime Merchan; Daniel G Tenen; Sanford D Markowitz; Balazs Halmos
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

2.  Mutations in KDSR Cause Recessive Progressive Symmetric Erythrokeratoderma.

Authors:  Lynn M Boyden; Nicholas G Vincent; Jing Zhou; Ronghua Hu; Brittany G Craiglow; Susan J Bayliss; Ilana S Rosman; Anne W Lucky; Luis A Diaz; Lowell A Goldsmith; Amy S Paller; Richard P Lifton; Susan J Baserga; Keith A Choate
Journal:  Am J Hum Genet       Date:  2017-06-01       Impact factor: 11.025

3.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

4.  High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships.

Authors:  Frank H Niesen; Lena Schultz; Ajit Jadhav; Chitra Bhatia; Kunde Guo; David J Maloney; Ewa S Pilka; Minghua Wang; Udo Oppermann; Tom D Heightman; Anton Simeonov
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.